Intercept Stock Analysis

ICPT
 Stock
  

USD 16.67  1.09  7.00%   

The newest price gain of Intercept Pharmaceuticals may raise some interest from private investors. The stock closed today at a share price of 16.67 on 789,264 in trading volume. The company executives may have good odds in positioning the firm resources to exploit market volatility in October. The stock standard deviation of daily returns for 90 days investing horizon is currently 5.18. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Intercept Pharmaceuticals partners.
Please see Risk vs Return Analysis.
  
The Intercept Pharmaceuticals stock analysis report makes it easy to digest most publicly released information about Intercept Pharmaceuticals and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Intercept Stock analysis module also helps to analyze the Intercept Pharmaceuticals price relationship with some important fundamental indicators such as market cap and management efficiency.

Intercept Stock Analysis Notes

About 97.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 8.34. Intercept Pharmaceuticals had not issued any dividends in recent years. Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company was incorporated in 2002 and is headquartered in New York, New York. Intercept Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 437 people. To learn more about Intercept Pharmaceuticals call Mark Pruzanski at 646 747 1000 or check out https://www.interceptpharma.com.

Intercept Pharmaceuticals Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Intercept Pharmaceuticals' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Intercept Pharmaceuticals or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Intercept Pharmaceuticals has very high historical volatility over the last 90 days
Intercept Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years
Intercept Pharmaceuticals has high financial leverage indicating that it may have difficulties to generate enough cash to satisfy its financial obligations
The company reported the previous year's revenue of 370.39 M. Net Loss for the year was (68.29 M) with profit before overhead, payroll, taxes, and interest of 360.37 M.
Intercept Pharmaceuticals currently holds about 395.7 M in cash with (7.11 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 13.32.
Over 97.0% of the company shares are owned by institutional investors
Latest headline from MacroaxisInsider: Payment of 908 shares by Saik Andrew of Intercept Pharmaceuticals subject to Rule 16b-3

Intercept Pharmaceuticals Upcoming and Recent Events

Earnings reports are used by Intercept Pharmaceuticals to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Intercept Pharmaceuticals previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report24th of February 2022
Next Financial Report5th of May 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End24th of February 2022
Last Quarter Report30th of September 2021
Last Financial Announcement31st of December 2020

Intercept Pharmaceuticals SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Intercept Pharmaceuticals prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Intercept Pharmaceuticals investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Intercept Pharmaceuticals specific information freely available to individual and institutional investors to make a timely investment decision.
12th of September 2022
Financial Statements and Exhibits. Entry into a Material Definitive Agreement
View
8th of September 2022
Unregistered Sales of Equity Securities
View
7th of September 2022
Financial Statements and Exhibits. Unregistered Sales of Equity Securities. Entry into a Material Definitive Agreement
View
6th of September 2022
Unregistered Sales of Equity Securities
View
2nd of September 2022
Financial Statements and Exhibits. Unclassified Corporate Event. Unregistered Sales of Equity Securities. Entry into a Material Definitive Agreement
View
26th of August 2022
Unregistered Sales of Equity Securities
View
19th of August 2022
Financial Statements and Exhibits. Other Events. Unregistered Sales of Equity Securities. Entry into a Material Definitive Agreement
View
18th of August 2022
Unclassified Corporate Event
View

Intercept Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Intercept Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Intercept Pharmaceuticals backward and forwards among themselves. Intercept Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Intercept Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Deerfield Management Company Lp Series CDebt57.8 M56.2 M
State Street CorpCommon Shares3.5 M48 M
Blackrock IncCommon Shares2.7 M37.5 M
Vanguard Group IncCommon Shares2.5 M34.7 M
Fmr LlcCommon Shares2.1 M28.5 M
Morgan StanleyCommon Shares1.1 M14.7 M
Eventide Asset Management LlcCommon Shares800 K11 M
Susquehanna International Group LlpCall Options736.9 K10.2 M
Jacobs Levy Equity Management IncCommon Shares645.7 K8.9 M
Note, although Intercept Pharmaceuticals' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Intercept Market Capitalization

The company currently falls under 'Small-Cap' category with current market capitalization of 450.3 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Intercept Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Intercept Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Intercept Profitablity

Intercept Pharmaceuticals' profitability indicators refer to fundamental financial ratios that showcase Intercept Pharmaceuticals' ability to generate income relative to its revenue or operating costs. If, let's say, Intercept Pharmaceuticals is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Intercept Pharmaceuticals' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Intercept Pharmaceuticals' profitability requires more research than a typical breakdown of Intercept Pharmaceuticals' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Profit Margin (PM) of (18.44) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (9.95) %, which suggests for every $100 dollars of sales, it generated a net operating loss of -0.1.

Management Efficiency

The entity has return on total asset (ROA) of (4.5) % which means that it has lost $4.5 on every $100 spent on asset. This is way below average. Intercept Pharmaceuticals management efficiency ratios could be used to measure how well intercept pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.

Technical Drivers

As of the 27th of September, Intercept Pharmaceuticals retains the Market Risk Adjusted Performance of 0.2648, downside deviation of 5.87, and Risk Adjusted Performance of 0.0854. Intercept Pharmaceuticals technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices. Simply put, you can use this information to find out if the firm will indeed mirror its model of historical price patterns, or the prices will eventually revert. We were able to interpolate data for nineteen technical drivers for Intercept Pharmaceuticals, which can be compared to its competitors. Please check out Intercept Pharmaceuticals information ratio, potential upside, as well as the relationship between the Potential Upside and kurtosis to decide if Intercept Pharmaceuticals is priced fairly, providing market reflects its last-minute price of 16.67 per share. Given that Intercept Pharmaceuticals has jensen alpha of 0.4301, we strongly advise you to confirm Intercept Pharmaceuticals's regular market performance to make sure the company can sustain itself at a future point.

Intercept Pharmaceuticals Price Movement Analysis

The output start index for this execution was thirty-four with a total number of output elements of twenty-seven. The Weighted Moving Average calculates a weight for each value in Intercept Pharmaceuticals price series with the more recent values given greater weights.
.

Intercept Pharmaceuticals Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Intercept Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Intercept Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Intercept Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Saik Andrew few days ago via Macroaxis 
Payment of 908 shares by Saik Andrew of Intercept Pharmaceuticals subject to Rule 16b-3
Berrey M Michelle over a week ago via Macroaxis 
Payment of 1246 shares by Berrey M Michelle of Intercept Pharmaceuticals subject to Rule 16b-3
Venezia Rocco over two weeks ago via Macroaxis 
Payment of 429 shares by Venezia Rocco of Intercept Pharmaceuticals subject to Rule 16b-3
Ball Bryan over two months ago via Macroaxis 
Payment of 436 shares by Ball Bryan of Intercept Pharmaceuticals subject to Rule 16b-3
Saik Andrew over three months ago via Macroaxis 
Payment of 3632 shares by Saik Andrew of Intercept Pharmaceuticals subject to Rule 16b-3
Berrey M Michelle over three months ago via Macroaxis 
Payment of 4984 shares by Berrey M Michelle of Intercept Pharmaceuticals subject to Rule 16b-3
Nancy MillerRich over three months ago via Macroaxis 
Acquisition by Nancy MillerRich of 12790 shares of Intercept Pharmaceuticals subject to Rule 16b-3
Richardson Linda M over three months ago via Macroaxis 
Payment of 124 shares by Richardson Linda M of Intercept Pharmaceuticals subject to Rule 16b-3
Daniel Bradbury over three months ago via Macroaxis 
Intercept Pharmaceuticals exotic insider transaction detected
Ball Bryan over three months ago via Macroaxis 
Payment of 531 shares by Ball Bryan of Intercept Pharmaceuticals subject to Rule 16b-3
Richardson Linda M over six months ago via Macroaxis 
Payment of 171 shares by Richardson Linda M of Intercept Pharmaceuticals subject to Rule 16b-3
Venezia Rocco over six months ago via Macroaxis 
Acquisition by Venezia Rocco of 6100 shares of Intercept Pharmaceuticals subject to Rule 16b-3

Intercept Pharmaceuticals Predictive Daily Indicators

Intercept Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Intercept Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Intercept Pharmaceuticals Forecast Models

Intercept Pharmaceuticals time-series forecasting models is one of many Intercept Pharmaceuticals' stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Intercept Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Intercept Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Intercept Pharmaceuticals prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Intercept shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual Stock such as Intercept Pharmaceuticals. By using and applying Intercept Stock analysis, traders can create a robust methodology for identifying Intercept entry and exit points for their positions.
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company was incorporated in 2002 and is headquartered in New York, New York. Intercept Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 437 people.

Current Intercept Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Intercept analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Intercept analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
32.31Hold13Odds
Intercept Pharmaceuticals current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Intercept analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Intercept stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Intercept Pharmaceuticals, talking to its executives and customers, or listening to Intercept conference calls.
Intercept Analyst Advice Details

Intercept Stock Analysis Indicators

Intercept Pharmaceuticals stock analysis indicators help investors evaluate how Intercept Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Intercept Pharmaceuticals shares will generate the highest return on investment. By understating and applying Intercept Pharmaceuticals stock analysis, traders can identify Intercept Pharmaceuticals position entry and exit signals to maximize returns.
Quick Ratio2.93
Fifty Two Week Low10.81
Revenue Growth8.50%
Shares Short Prior Month9.76M
Average Daily Volume Last 10 Day1.17M
Average Daily Volume In Three Month968.38k
Shares Percent Shares Out34.80%
Gross Margins99.18%
Short Percent Of Float49.19%
Forward Price Earnings-4.79
Float Shares24.68M
Fifty Two Week High21.25
Enterprise Value To Ebitda-20.64
Fifty Day Average16.33
Two Hundred Day Average15.95
Enterprise Value To Revenue1.91
Please see Risk vs Return Analysis. You can also try Watchlist Optimization module to optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm.

Complementary Tools for analysis

When running Intercept Pharmaceuticals price analysis, check to measure Intercept Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Intercept Pharmaceuticals is operating at the current time. Most of Intercept Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Intercept Pharmaceuticals' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Intercept Pharmaceuticals' price. Additionally, you may evaluate how the addition of Intercept Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Go
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Go
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Go
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Go
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Go
Shere Portfolio
Track or share privately all of your investments from the convenience of any device
Go
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Go
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Go
Is Intercept Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Intercept Pharmaceuticals. If investors know Intercept will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Intercept Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Intercept Pharmaceuticals is measured differently than its book value, which is the value of Intercept that is recorded on the company's balance sheet. Investors also form their own opinion of Intercept Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Intercept Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Intercept Pharmaceuticals' market value can be influenced by many factors that don't directly affect Intercept Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Intercept Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine Intercept Pharmaceuticals value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Intercept Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.